Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | PDE5A | O76074 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24462561 | 0.92 | PPARD (0.42) | PPARDMAPTKDM4EALDH1A1POLB | |
| SCHEMBL11434763 | 0.87 | KMT2A (0.43) | PPARDMAPTKDM4EALDH1A1POLB | |
| SCHEMBL7444967 | 0.87 | PPARD (0.41) | PPARDMAPTKDM4EALDH1A1POLB | |
| SCHEMBL13992732 | 0.85 | PPARD (0.40) | PPARDMAPTTSHRMEN1GAA | |
| SCHEMBL22014309 | 0.77 | TSHR (0.50) | PPARDMAPTKDM4EALDH1A1POLB | |
| SCHEMBL22014094 | 0.77 | MAPT (0.48) | MAPTKDM4EALDH1A1POLBMEN1 | |
| SCHEMBL14204465 | 0.75 | MAPT (0.56) | MAPTKDM4EALDH1A1POLBMEN1 | |
| SCHEMBL13631583 | 0.71 | TSHR (0.43) | PPARDKDM4EALDH1A1POLBTSHR | |
| SCHEMBL1661755 | 0.71 | — | — | |
| SCHEMBL6030230 | 0.71 | PPARD (0.76) | PPARDPOLBTSHRTP53TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250319214-A1 | A NOVEL KIT FOR RADIOPHARMACEUTICAL PREPARATION OF A RADIOMETAL LABELED CHELATE-FUNCTIONALIZED TARGETING CONJUGATE | Life Molecular Imaging Ltd. (GB) | 2025-10-16 | — | — | US | claimed |
| EP-4362989-A2 | A NOVEL KIT FOR RADIOPHARMACEUTICAL PREPARATION OF A RADIOMETAL LABELED CHELATE-FUNCTIONALIZED TARGETING CONJUGATE | Life Molecular Imaging Limited (GB) | 2024-05-08 | — | — | EP | claimed |
| CN-117580595-A | Novel kit for radiolabelled chelator functionalized targeted conjugate radiopharmaceutical formulations | 生命分子影像有限公司 | 2024-02-20 | — | — | CN | claimed |
| WO-2023275195-A2 | A NOVEL KIT FOR RADIOPHARMACEUTICAL PREPARATION OF A RADIOMETAL LABELED CHELATE-FUNCTIONALIZED TARGETING CONJUGATE | LIFE MOLECULAR IMAGING LIMITED (GB) | 2023-01-05 | — | — | WO | claimed |
| US-20260102524-A1 | KIT FOR RADIOLABELLING WITH 68GA COMPRISING A METAL INHIBITOR | Telix Innovations S.A. (BE) | 2026-04-16 | — | — | US | disclosed |
| US-20250319214-A1 | A NOVEL KIT FOR RADIOPHARMACEUTICAL PREPARATION OF A RADIOMETAL LABELED CHELATE-FUNCTIONALIZED TARGETING CONJUGATE | Life Molecular Imaging Ltd. (GB) | 2025-10-16 | — | — | US | disclosed |
| US-12329829-B2 | Kit for radiolabelling with 68GA comprising a metal inhibitor | Telix Innovations S.A. (BE) | 2025-06-17 | — | — | US | disclosed |
| CN-117580595-A | Novel kit for radiolabelled chelator functionalized targeted conjugate radiopharmaceutical formulations | 生命分子影像有限公司 | 2024-02-20 | — | — | CN | disclosed |
| WO-2023275195-A2 | A NOVEL KIT FOR RADIOPHARMACEUTICAL PREPARATION OF A RADIOMETAL LABELED CHELATE-FUNCTIONALIZED TARGETING CONJUGATE | LIFE MOLECULAR IMAGING LIMITED (GB) | 2023-01-05 | — | — | WO | disclosed |
| WO-2022232124-A1 | TARGETED ALPHA PARTICLE THERAPY FOR SOMATOSTATIN RECEPTOR 2 POSITIVE NEUROENDOCRINE TUMORS AND METASTASES | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2022-11-03 | — | — | WO | disclosed |
| US-20220296735-A1 | KIT FOR RADIOLABELLING WITH 68GA COMPRISING A METAL INHIBITOR | Telix Innovations S.A. (BE) | 2022-09-22 | — | — | US | disclosed |
| US-20220273827-A1 | KIT FOR RADIOLABELLING WITH 68GA COMPRISING A METAL INHIBITOR | Telix Innovations S.A. (BE) | 2022-09-01 | — | — | US | disclosed |
| US-20220265870-A1 | MULTIVALENT FIBROBLAST-TARGETED AGENTS AND METHODS OF USE | PURDUE RESEARCH FOUNDATION | 2022-08-25 | — | — | US | disclosed |
| CN-114832119-A | Radioactive gel microsphere and preparation method and application thereof | 苏州大学 | 2022-08-02 | — | — | CN | disclosed |
| EP-4003321-A1 | MULTIVALENT FIBROBLAST-TARGETED AGENTS AND METHODS OF USE | Purdue Research Foundation (US) | 2022-06-01 | — | — | EP | disclosed |
| US-11344635-B2 | Compounds for use as iron (III) MRI contrast agents containing anionic pendents and ancillary groups | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2022-05-31 | — | — | US | disclosed |
| US-11344635-B2 | Compounds for use as iron (III) MRI contrast agents containing anionic pendents and ancillary groups | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2022-05-31 | — | — | US | disclosed |
| CN-114340610-A | Multivalent fibroblast targeting agents and methods of use | 普渡研究基金会 | 2022-04-12 | — | — | CN | disclosed |
| WO-2020102820-A1 | COMPOUNDS FOR USE AS IRON (III) MRI CONTRAST AGENTS CONTAINING ANIONIC PENDENTS AND ANCILLARY GROUPS | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2020-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260102524-A1 | KIT FOR RADIOLABELLING WITH 68GA COMPRISING A METAL INHIBITOR | KIT, CTSD, NGLY1 | PPARD 1625/4885MAPT 3549/4885KDM4E 2785/4885 |
| US-20220265870-A1 | MULTIVALENT FIBROBLAST-TARGETED AGENTS AND METHODS OF USE | FIBP, FAP, MFAP1 | PPARD 3571/4885MAPT 3151/4885KDM4E 3637/4885 |
| US-11344635-B2 | Compounds for use as iron (III) MRI contrast agents containing anionic pendents and ancillary groups | SLC40A1, TAC3, ABCB7 | PPARD 4086/4885MAPT 1870/4885KDM4E 4435/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.